Anakinra Market is Projected to Grow Expeditiously: to Reach $8.6 Billion by 2029

 This report provides practical insights for business leaders looking to understand market growth, size, and key trends in the anakinra industry.

How Much Is The Anakinra Market Worth?

The anakinra market size has grown rapidly in recent years. It will grow from $4.89 billion in 2024 to $5.46 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to the increasing prevalence of rheumatoid arthritis, the approval of anakinra for treating rare autoinflammatory conditions like NOMID, rising awareness of biologics for managing chronic inflammatory conditions, and growing adoption of targeted therapies.



The anakinra market size is expected to see rapid growth in the next few years. It will grow to $8.6 billion in 2029 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to the expansion of indications for anakinra in conditions, increasing focus on personalized medicine, rising prevalence of rare autoinflammatory disorders, advancements in drug delivery systems, and growing healthcare access in emerging markets driving demand for biologics. Major trends in the forecast period include the development of biosimilars and next-generation IL-1 inhibitors, the adoption of home-based and self-administered treatment options, collaborations between biotech companies and academic institutions, and digital health solutions to support patient adherence.



Get your free sample today:

Anakinra Global Market Insights And Outlook To 2034 Sample



What Are The Current Leading Growth Drivers For Anakinra Market?

The rising incidence of autoimmune disorders is expected to propel the growth of the anakinra market going forward. Autoimmune disorders refer to problems that occur when the body's immune system incorrectly assaults and destroys its own healthy tissues and organs, viewing them as foreign invaders. The rising incidence of autoimmune disorders is driven by genetic predisposition and environmental factors, such as infections, pollution, and dietary changes, all contributing to the growing occurrence of these disorders. Anakinra is used to treat autoimmune disorders by blocking interleukin-1 (IL-1) activity, reducing inflammation in conditions like rheumatoid arthritis, Still’s disease, and periodic fever syndromes. For instance, in June 2024, according to a report published by the Australian Institute of Health and Welfare, an Australian-based governmental organization, in 2021–22, there were 10,000 hospitalizations for rheumatoid arthritis, a 25% increase from the previous year's 8,000, equating to a rate of 39 hospitalizations per 100,000 population. Therefore, the rising incidence of autoimmune disorders is driving the growth of the anakinra market.



Which Segment Accounted For The Largest Anakinra Market Share?

The anakinra market covered in this report is segmented –



1) By Indication: Rheumatoid Arthritis, Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, Neonatal-Onset Multisystem Inflammatory Disease, Other Indications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Wholesale Pharmacies

3) By End-User: Hospitals, Clinics, Homecare Settings



Subsegments:

1) By Rheumatoid Arthritis: Moderate-to-Severe Disease, Early-stage Disease

2) By Cryopyrin-Associated Periodic Syndromes: Muckle-Wells Syndrome, Neonatal-Onset Multisystem Inflammatory Disease

3) By Familial Cold Autoinflammatory Syndrome: Acute Episodes, Chronic Symptoms

4) By Systemic Juvenile Idiopathic Arthritis: Active Systemic Disease, Inactive Disease With Flares

5) By Adult-Onset Still's Disease: Active Disease, Remission Induction

6) By Neonatal-Onset Multisystem Inflammatory Disease: Acute Disease Episodes, Long-term Disease Management

7) By Other Indications: Gouty Arthritis, Osteoarthritis, Spondyloarthritis



Anakinra Market Future Trends

Major companies operating in Anakinra market are gaining regulatory approvals to expand indications for new therapeutic applications. Regulatory approvals refer to official authorizations from government agencies that allow a drug to be marketed and prescribed for specific medical conditions after evaluating its safety, efficacy, and quality. For instance, in November 2022, the Food and Drug Administration, a US-based government agency, granted Emergency Use Authorization (EUA) for Kineret (anakinra) to treat hospitalized adults with COVID-19-related pneumonia requiring supplemental oxygen, aiming to reduce the risk of severe respiratory failure. The authorization was based on the SAVE-MORE phase 3 study, which showed that early treatment with Kineret improved patient outcomes. Kineret works by blocking cytokines IL-1a and IL-1ß, which contribute to the hyperinflammatory response in severe COVID-19 cases. While it is not fully FDA-approved for this indication, it is authorized for temporary use during the public health emergency.



Which Are The Top Companies To Hold The Market Share In Anakinra Market?

Major companies operating in the anakinra market are Swedish Orphan Biovitrum AB, Boehringer Ingelheim, Amgen Inc.



View the full anakinra market report here:

Anakinra Global Market Insights And Outlook To 2034



Which Region Is Projected To Account For The Largest Share Of The Anakinra Market?

North America was the largest region in the anakinra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anakinra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.



Contact Us:



The Business Research Company



Market Research Reports



Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267



Email: info@tbrc.info





Follow Us On:



LinkedIn: The Business Research Company | LinkedIn